Abstract
Because of the high concentrations of γ-aminobutyric acid (GABA) in the cerebellar cortex and nuclei, an attempt was made to enhance GABAergic transmission in patients with cerebellar disease. Maximum tolerated doses of sodium valproate, a drug which inhibits the degradation of GABA, failed to influence cerebellar deficits in a double blind crossover study on six patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 455-457 |
| Number of pages | 3 |
| Journal | Canadian Journal of Neurological Sciences |
| Volume | 6 |
| Issue number | 4 |
| State | Published - 1979 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)
Cite this
Sodium valproic in the treatment of cerebellar disorders. / Neophytides, A. N.; Teychenne, P. F.; Pfeiffer, Ronald; Calne, D. B.
In: Canadian Journal of Neurological Sciences, Vol. 6, No. 4, 1979, p. 455-457.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Sodium valproic in the treatment of cerebellar disorders
AU - Neophytides, A. N.
AU - Teychenne, P. F.
AU - Pfeiffer, Ronald
AU - Calne, D. B.
PY - 1979
Y1 - 1979
N2 - Because of the high concentrations of γ-aminobutyric acid (GABA) in the cerebellar cortex and nuclei, an attempt was made to enhance GABAergic transmission in patients with cerebellar disease. Maximum tolerated doses of sodium valproate, a drug which inhibits the degradation of GABA, failed to influence cerebellar deficits in a double blind crossover study on six patients.
AB - Because of the high concentrations of γ-aminobutyric acid (GABA) in the cerebellar cortex and nuclei, an attempt was made to enhance GABAergic transmission in patients with cerebellar disease. Maximum tolerated doses of sodium valproate, a drug which inhibits the degradation of GABA, failed to influence cerebellar deficits in a double blind crossover study on six patients.
UR - http://www.scopus.com/inward/record.url?scp=0018651485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0018651485&partnerID=8YFLogxK
M3 - Article
C2 - 120757
AN - SCOPUS:0018651485
VL - 6
SP - 455
EP - 457
JO - Canadian Journal of Neurological Sciences
JF - Canadian Journal of Neurological Sciences
SN - 0317-1671
IS - 4
ER -